Intec Pharma Ltd. (NASDAQ:NTEC) had its price target raised by Oppenheimer Holdings, Inc. from $10.00 to $15.00 in a report released on Thursday. Oppenheimer Holdings, Inc. currently has an outperform rating on the biotechnology company’s stock.

Several other analysts have also issued reports on NTEC. Zacks Investment Research lowered Intec Pharma from a hold rating to a sell rating in a research note on Tuesday, August 15th. Roth Capital set a $10.00 target price on Intec Pharma and gave the company a buy rating in a research report on Thursday, August 10th. ValuEngine downgraded Intec Pharma from a hold rating to a sell rating in a research report on Friday, June 9th. Finally, Maxim Group set a $9.00 target price on Intec Pharma and gave the company a buy rating in a research report on Wednesday, May 24th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of Buy and an average target price of $10.90.

Shares of Intec Pharma (NTEC) traded up 1.70% during mid-day trading on Thursday, hitting $8.95. The stock had a trading volume of 42,199 shares. The stock has a 50 day moving average of $7.75 and a 200-day moving average of $7.75. The stock’s market capitalization is $122.96 million. Intec Pharma has a 52 week low of $4.20 and a 52 week high of $9.05.

COPYRIGHT VIOLATION WARNING: “Intec Pharma Ltd. (NTEC) Price Target Raised to $15.00 at Oppenheimer Holdings, Inc.” was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another site, it was copied illegally and reposted in violation of U.S. & international copyright laws. The correct version of this article can be accessed at https://www.dailypolitical.com/2017/09/22/intec-pharma-ltd-ntec-price-target-raised-to-15-00-at-oppenheimer-holdings-inc.html.

An institutional investor recently raised its position in Intec Pharma stock. Migdal Insurance & Financial Holdings Ltd. grew its position in Intec Pharma Ltd. (NASDAQ:NTEC) by 5.0% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 522,200 shares of the biotechnology company’s stock after purchasing an additional 25,000 shares during the quarter. Migdal Insurance & Financial Holdings Ltd. owned about 3.80% of Intec Pharma worth $2,977,000 as of its most recent SEC filing. Institutional investors own 16.41% of the company’s stock.

Intec Pharma Company Profile

Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs.

Receive News & Ratings for Intec Pharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.